Le Lézard
Classified in: Health, Science and technology
Subject: FEA

IntegriChain Secures 25 Life Sciences Gross-to-Net Customers


PHILADELPHIA, Nov. 10, 2020 /PRNewswire/ -- IntegriChain, delivering Life Sciences' only comprehensive data and business process platform for market access, today announced that the Company now has 25 customers of all size and complexity for its Gross-to-Net (GTN) offerings. IntegriChain's GTN solutions enable Life Sciences Market Access and Finance teams to improve forecast accuracy, GTN modeling, and financial close efficiency. The GTN suite comprises GTN Accrual Management and GTN Accrual Forecasting, and newly announced GTN Analytics (press release). IntegriChain's GTN offerings are delivered in flexible options as Managed Services (which were launched just a year ago), software-as-a-service (SaaS), or hybrid implementations.

"We are thrilled with the market uptake of our GTN solutions," said Jennifer Sharpe, Executive Director, Gross-to-Net. "The more than two dozen manufacturers ? representing all segments of the Life Sciences industry from emerging innovators to mid-tier and Big Pharma enterprises ? share our vision for a single, credible system of truth and forecast accuracy to drive decision-making and strategy. We are excited to partner with these innovative manufacturers as we continue to grow and expand our GTN offerings."

IntegriChain Sponsors CBI GTN 2020

As leaders in GTN, IntegriChain is a platinum sponsor of CBI GTN 2020, which begins virtually on November 16. Throughout the conference, IntegriChain experts will share their GTN thought leadership:

About IntegriChain's GTN Solutions

IntegriChain offers a full suite of GTN Solutions, including:

GTN Accrual Management. An end-to-end solution for Market Access and Finance departments, pre-configured for all standard line items with robust out-of-the-box accrual methodologies, including inventory and pipeline adjustments to accruals, balance sheet reconciliation to ERP systems, and true-up functionality.

GTN Accrual Forecasting. Based on industry-standard forecast methodologies configured for each liability line item with the ability to execute multiple scenario analyses for forecasts along with functionality to compare scenarios to improve forecast accuracy, GTN modeling, and financial close efficiency.

GTN Analytics. Delivering visibility to comprehensive market access datasets that power the accuracy of GTN accruals and forecasting processes, best practices GTN reports and metrics, and visualizations of GTN trends that allow for better accrual and net-price predictability and decision-making.

GTN Advisory. IntegriChain industry experts routinely advise manufacturers on GTN readiness for launch, GTN process assessments, and GTN market analysis.

About IntegriChain
IntegriChain delivers Life Sciences' only comprehensive data and business process platform for market access. More than 250 manufacturers rely on IntegriChain's ICyte Platform of analytics, applications, managed services, and expert advisors to power their market access operations and harness the value of their channel, patient and payer data. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.

Contact
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | [email protected]

SOURCE IntegriChain


These press releases may also interest you

at 07:00
In recognition of Clinical Trials Day, The Trial for #ClinicalEquality ?a longstanding and widely celebrated initiative from FCB Health New York, an IPG Health company ? continues the fight to increase equity in clinical trials with the next phase of...

at 06:52
According to the latest BCC Research study, the demand for the Global Prenatal Testing Market is expected to grow from $10.9 billion in 2023 and is projected to reach $19.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 12.6%...

at 06:32
"According to the latest BCC Research study, the demand for Medical Robotics and Computer-assisted Surgery: The Global Market is expected to grow from $11.5 billion in 2023 and is projected to reach $19.5 billion by the end of 2028, at a compound...

at 06:15
The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team...

at 06:07
Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two...

at 06:05
Arrowhead Pharmaceuticals, Inc. today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS)...



News published on and distributed by: